Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 536

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 2
Chunk 536
---
 Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission
    on November 6, 2013).
  
    10.4#
     
    Form
    of Incentive Stock Option Agreement (incorporated herein by reference to Exhibit 10.12 to the Current Report on Form 8-K of Imprimis
    Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on September 21, 2007). 
  
    10.5#
     
    Form
    of Non-Qualified Stock Option Agreement (incorporated herein by reference to Exhibit 10.13 to the Current Report on Form 8-K of Imprimis
    Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on September 21, 2007). 
  
    10.6#
     
    Form
    of Restricted Stock Unit Agreement (incorporated herein by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q of Imprimis
    Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on May 8, 2013).
  
    10.7#
     
    Employment
    Agreement, dated as of April 25, 2016, by and between Imprimis Pharmaceuticals, Inc. and Mark L. Baum (incorporated herein by reference
    to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 26,
    2016).
  
    10.8#
     
    Employment
    Agreement, dated as of April 25, 2016, by and between Imprimis Pharmaceuticals, Inc. and Andrew R. Boll (incorporated herein by reference
    to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 26,
    2016).
  
    10.9#
     
    Employment
    Agreement, dated as of April 25, 2016, by and between Imprimis Pharmaceuticals, Inc. and John P. Saharek (incorporated herein by
    reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on
    April 26, 2016).
  
    10.10
     
    License
    Agreement dated April 1, 2017 between Imprimis Pharmaceuticals,